Growth hormone deficiency testing and treatment following mild traumatic brain injury

Abstract Pituitary dysfunction, specifically growth hormone (GH) deficiency, can occur following traumatic brain injury. Our objective was to characterize the prevalence of GH deficiency (GHD) testing and response to recombinant human GH (rhGH) treatment in adults with persistent symptoms following...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Leah J. Mercier, Natalia Kruger, Quynk B. Le, Tak S. Fung, Gregory A. Kline, Chantel T. Debert
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/92a2b005d0f9445f957dcaed328da910
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:92a2b005d0f9445f957dcaed328da910
record_format	dspace
spelling	oai:doaj.org-article:92a2b005d0f9445f957dcaed328da9102021-12-02T17:32:59ZGrowth hormone deficiency testing and treatment following mild traumatic brain injury10.1038/s41598-021-87385-72045-2322https://doaj.org/article/92a2b005d0f9445f957dcaed328da9102021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87385-7https://doaj.org/toc/2045-2322Abstract Pituitary dysfunction, specifically growth hormone (GH) deficiency, can occur following traumatic brain injury. Our objective was to characterize the prevalence of GH deficiency (GHD) testing and response to recombinant human GH (rhGH) treatment in adults with persistent symptoms following mild traumatic brain injury (mTBI) referred for assessment of pituitary dysfunction. A retrospective chart review was conducted of patients seen at an outpatient brain injury clinic with a diagnosis of mTBI and persistent post-concussive symptoms who were referred to endocrinology. Clinical assessments of symptoms were collected. Investigations and results of GHD were collected, including initiation of rhGH treatment and treatment response. Of the 253 patients seen in both brain injury and endocrinology clinics, 97 with mTBI were referred for investigation of pituitary dysfunction and 73 (75%) had dynamic testing for assessment of GHD. Of the 26 individuals diagnosed with GHD, 23 (88%) started rhGH. GH therapy was inconsistently offered based on interpretation of GH dynamic testing results. Of those who started rhGH, 18 (78%) had a useful treatment response. This study suggests that clinical management of these patients is varied, highlighting a need for clear guidelines for the diagnosis and management of GHD following mTBI.Leah J. MercierNatalia KrugerQuynk B. LeTak S. FungGregory A. KlineChantel T. DebertNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Leah J. Mercier Natalia Kruger Quynk B. Le Tak S. Fung Gregory A. Kline Chantel T. Debert Growth hormone deficiency testing and treatment following mild traumatic brain injury
description	Abstract Pituitary dysfunction, specifically growth hormone (GH) deficiency, can occur following traumatic brain injury. Our objective was to characterize the prevalence of GH deficiency (GHD) testing and response to recombinant human GH (rhGH) treatment in adults with persistent symptoms following mild traumatic brain injury (mTBI) referred for assessment of pituitary dysfunction. A retrospective chart review was conducted of patients seen at an outpatient brain injury clinic with a diagnosis of mTBI and persistent post-concussive symptoms who were referred to endocrinology. Clinical assessments of symptoms were collected. Investigations and results of GHD were collected, including initiation of rhGH treatment and treatment response. Of the 253 patients seen in both brain injury and endocrinology clinics, 97 with mTBI were referred for investigation of pituitary dysfunction and 73 (75%) had dynamic testing for assessment of GHD. Of the 26 individuals diagnosed with GHD, 23 (88%) started rhGH. GH therapy was inconsistently offered based on interpretation of GH dynamic testing results. Of those who started rhGH, 18 (78%) had a useful treatment response. This study suggests that clinical management of these patients is varied, highlighting a need for clear guidelines for the diagnosis and management of GHD following mTBI.
format	article
author	Leah J. Mercier Natalia Kruger Quynk B. Le Tak S. Fung Gregory A. Kline Chantel T. Debert
author_facet	Leah J. Mercier Natalia Kruger Quynk B. Le Tak S. Fung Gregory A. Kline Chantel T. Debert
author_sort	Leah J. Mercier
title	Growth hormone deficiency testing and treatment following mild traumatic brain injury
title_short	Growth hormone deficiency testing and treatment following mild traumatic brain injury
title_full	Growth hormone deficiency testing and treatment following mild traumatic brain injury
title_fullStr	Growth hormone deficiency testing and treatment following mild traumatic brain injury
title_full_unstemmed	Growth hormone deficiency testing and treatment following mild traumatic brain injury
title_sort	growth hormone deficiency testing and treatment following mild traumatic brain injury
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/92a2b005d0f9445f957dcaed328da910
work_keys_str_mv	AT leahjmercier growthhormonedeficiencytestingandtreatmentfollowingmildtraumaticbraininjury AT nataliakruger growthhormonedeficiencytestingandtreatmentfollowingmildtraumaticbraininjury AT quynkble growthhormonedeficiencytestingandtreatmentfollowingmildtraumaticbraininjury AT taksfung growthhormonedeficiencytestingandtreatmentfollowingmildtraumaticbraininjury AT gregoryakline growthhormonedeficiencytestingandtreatmentfollowingmildtraumaticbraininjury AT chanteltdebert growthhormonedeficiencytestingandtreatmentfollowingmildtraumaticbraininjury
_version_	1718380134942113792

Growth hormone deficiency testing and treatment following mild traumatic brain injury

Ejemplares similares